{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:26:04Z","timestamp":1773923164568,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":3021,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["PO1 CA108671-01A2"],"award-info":[{"award-number":["PO1 CA108671-01A2"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.bbmt.2006.11.003","type":"journal-article","created":{"date-parts":[[2007,1,11]],"date-time":"2007-01-11T07:59:01Z","timestamp":1168502341000},"page":"64-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"S1","title":["Philadelphia Chromosome\u2013Negative Myeloproliferative Disorders: Biology and Treatment"],"prefix":"10.1016","volume":"13","author":[{"given":"Ronald","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef T.","family":"Prchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Samuelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Rondelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2006.11.003_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique JAK2 mutation leading to constitute signaling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2006.11.003_bib3","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.bbmt.2006.11.003_bib4","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Bone marrow responses in polycythemia vera","volume":"290","author":"Prchal","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.11.003_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V83.1.99.99","article-title":"Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium","volume":"83","author":"Correa","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood.V80.4.891.891","article-title":"Polycythemia vera, II: hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocytes macrophage colony-stimulating factor","volume":"80","author":"Dai","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib7","first-page":"733a","article-title":"Differences in gene expression between normal and polycythemia vera CD34 cells","volume":"86","author":"Kralovics","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood.V90.1.97.97_97_104","article-title":"Selective expression of mRNA coding for the truncated form of erythropoietin receptor in hematopoietic cells and its decrease in patients with polycythemia vera","volume":"90","author":"Chiba","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib9","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood.V95.8.2569","article-title":"Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera","volume":"95","author":"Temerinac","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM199802263380902","article-title":"Expression of Bcl-x in erythroid precursors from patients with polycythemia vera","volume":"338","author":"Silva","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.11.003_bib11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V97.11.3424","article-title":"Increased expression of the INK4a\/ARF locus in polycythemia vera","volume":"97","author":"Dai","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.V90.2.651","article-title":"Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells","volume":"90","author":"Sui","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2006.11.003_bib14","series-title":"Myeloproliferative Diseases","first-page":"297","article-title":"The polycythemia vera and other polycythemic disorders: biological aspects","author":"Ang","year":"2006"},{"key":"10.1016\/j.bbmt.2006.11.003_bib15","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1097-2765(01)00401-4","article-title":"The N-terminal domain of Janus kinase 2 is required for golgi processing and cell surface expression of erythropoietin receptor","volume":"8","author":"Huang","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.bbmt.2006.11.003_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.exphem.2003.11.003","article-title":"Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera","volume":"32","author":"Ugo","year":"2004","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2006.11.003_bib17","first-page":"411","article-title":"The effect of the JAK2 V617F mutation of PRV-1 expression","volume":"91","author":"Mnjoyan","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2006.11.003_bib18","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2006.11.003_bib19","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.11.003_bib20","first-page":"1","article-title":"The molecular basis of polycythemia vera unraveled?","volume":"2","author":"Emanuel","year":"2005","journal-title":"The Hematologist"},{"key":"10.1016\/j.bbmt.2006.11.003_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythaemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbmt.2006.11.003_bib22","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib23","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome\u2013negative CML, and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2006.11.003_bib25","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1182\/blood-2005-08-3319","article-title":"High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension","volume":"107","author":"Popat","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib26","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bbmt.2006.11.003_bib28","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/archinte.165.22.2651","article-title":"Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis and leukemia","volume":"165","author":"Chim","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bbmt.2006.11.003_bib29","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1053\/j.gastro.2006.04.008","article-title":"Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome","volume":"130","author":"Patel","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbmt.2006.11.003_bib30","series-title":"Introduction in Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues","first-page":"17","article-title":"Chronic myeloproliferative diseases","author":"Vardiman","year":"2001"},{"key":"10.1016\/j.bbmt.2006.11.003_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2006.11.003_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations and role in leukemic transformation","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib33","first-page":"489","article-title":"Risk-adapted therapy in essential thrombocythemia and polycythemia vera","volume":"74","author":"Finazzi","year":"2005","journal-title":"Blood Rev"},{"key":"10.1016\/j.bbmt.2006.11.003_bib34","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib35","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"United Kingdom Medical Research Council Primary Thrombocythemia 1 Study","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.11.003_bib37","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2004-06-2485","article-title":"The constitutive mobilization of bone marrow-repopulation cells into the peripheral blood in idiopathic myelofibrosis","volume":"105","author":"Xu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib38","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1200\/JCO.2005.09.021","article-title":"Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia","volume":"23","author":"Massa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2006.11.003_bib39","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood-2004-08-3238","article-title":"MPD Research Consortium","volume":"105","author":"Xu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib40","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","article-title":"Myeloproliferative Diseases Research Consortium","volume":"105","author":"Rondelli","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib41","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/cncr.21644","article-title":"Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system","volume":"106","author":"Dingli","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2006.11.003_bib43","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.21868","article-title":"Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis","volume":"106","author":"Dingli","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2006.11.003_bib44","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2141.1997.3083125.x","article-title":"Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis","volume":"98","author":"Anderson","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2006.11.003_bib45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.1992.tb06958.x","article-title":"Allogeneic bone marrow transplantation for primary myelofibrosis","volume":"82","author":"Creemers","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2006.11.003_bib46","first-page":"743","article-title":"Allogeneic bone marrow transplantation for primary myelofibrosis","volume":"16","author":"Singhal","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.003_bib47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<24::AID-AJH4>3.0.CO;2-3","article-title":"Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases","volume":"57","author":"Przepiorka","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2006.11.003_bib48","first-page":"2831","article-title":"Allogeneic stem cell transplantation for agnogenic myeloid metaplasia","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.bmt.1704075","article-title":"Stem cell transplantation for myelofibrosis: a report from two Canadian centers","volume":"32","author":"Daly","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.003_bib50","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib51","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1046\/j.1365-2141.2000.01826.x","article-title":"Induction of remission after donor leukocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogenic transplantation: evidence for a \u201cgraft vs myelofibrosis\u201d effect","volume":"108","author":"Byrne","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2006.11.003_bib52","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJM200008313430913","article-title":"Myelofibrosis with myeloid metaplasia","volume":"343","author":"Guardiola","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.11.003_bib53","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V98.3.586","article-title":"Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myelofibrosis","volume":"98","author":"Anderson","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2404334","article-title":"Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents","author":"Barrett","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2006.11.003_bib55","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V99.6.2255","article-title":"Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia","volume":"99","author":"Devine","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib56","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2141.2005.05373.x","article-title":"Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis","volume":"128","author":"Kroger","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2006.11.003_bib57","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1309\/7A5JU9KJK89VQPH9","article-title":"Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis","volume":"123","author":"Ni","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.bbmt.2006.11.003_bib58","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","article-title":"Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study","volume":"6","author":"Andersson","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.003_bib59","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.003_bib60","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib61","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.bmt.1705480","article-title":"Comparable kinetics of myeloablation between fludarabine\/full-dose busulfan and fludarabine\/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation","volume":"38","author":"Chunduri","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.11.003_bib62","first-page":"200","article-title":"Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction","volume":"7","author":"Barosi","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2006.11.003_bib63","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib64","first-page":"3630","article-title":"Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia","volume":"91","author":"Barosi","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib65","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood.V97.7.2180","article-title":"Splenectomy and hemopoietic stem cell transplantation for myelofibrosis","volume":"97","author":"Li","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib66","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood-2005-04-1520","article-title":"Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)","volume":"106","author":"Barosi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib67","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.11.003_bib68","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bbmt.2006.06.014","article-title":"Allogeneic Hematopoietic Cell Transplantation following Reduced Intensity Conditioning for Treatment of Myelofibrosis","volume":"12","author":"Snyder","year":"2006","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879106007580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879106007580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:29:55Z","timestamp":1761056995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879106007580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":68,"alternative-id":["S1083879106007580"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2006.11.003","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Philadelphia Chromosome\u2013Negative Myeloproliferative Disorders: Biology and Treatment","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2006.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}